Corneal Crosslinking Treatment Study

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Three different protocols for inducing corneal crosslinks in subjets with progressive keratoconus will be evaluated in this randomised clinical study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Region Skane
• Treatments: Riboflavin

Criteria

Inclusion Criteria:

• Progress in keratoconic eye. We define progress as an increase in Kmax of 1.0 diopter in 1 year or 0.5 diopter in 6 months. This increase in Kmax will be accepted as progression if concomitant changes tomographic parameters.

Exclusion Criteria:

• Concurrent ocular infection or corneal disease other than keratoconus.

• Pregnancy.

• Treatment with Isotretinoin.